Oscar Health Inc (NYSE:OSCR)’s traded shares stood at 0.56 million during the latest session, with the company’s beta value hitting 1.63. At the last check today, the stock’s price was $16.26, to imply a decrease of -5.47% or -$0.94 in intraday trading. The OSCR share’s 52-week high remains $23.79, putting it -46.31% down since that peak but still an impressive 70.97% since price per share fell to its 52-week low of $4.72. The company has a valuation of $3.93B, with an average of 2.8 million shares in intraday trading volume over the past 10 days and average of 2.95 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Oscar Health Inc (OSCR), translating to a mean rating of 1.86. Of 5 analyst(s) looking at the stock, 0 analyst(s) give OSCR a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.17.

Oscar Health Inc (NYSE:OSCR) trade information

After registering a -5.47% downside in the latest session, Oscar Health Inc (OSCR) has traded red over the past five days. The 5-day price performance for the stock is -0.55%, and -20.61% over 30 days. With these gigs, the year-to-date price performance is 77.70%. Short interest in Oscar Health Inc (NYSE:OSCR) saw shorts transact 12.02 million shares and set a 3.69 days time to cover.

The extremes give us $5 and $28 for target low and target high price respectively. As such, OSCR has been trading -72.2% off suggested target high and 69.25% from its likely low.

Oscar Health Inc (OSCR) estimates and forecasts

Looking at statistics comparing Oscar Health Inc share performance against respective industry, we note that the company has outperformed competitors. Oscar Health Inc (OSCR) shares are -7.40% down over the last 6 months, with its year-to-date growth rate higher than industry average at 100.82% against 12.20%. Revenue is forecast to grow 41.40% this quarter before jumping 13.60% for the next one. The rating firms project that company’s revenue will grow 54.20% compared to the previous financial year.

Revenue forecast for the current quarter as set by 6 analysts is 2.34B. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 2.34B.Earnings reports from the last fiscal year show that sales brought in 1.44B and 1.43B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 62.40% before jumping 63.50% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.85% for the past 5-year period. While 2024 is set for a 105.05% return in earnings, projections for the next 5 years are at 71.00% annually.

OSCR Dividends

Oscar Health Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Oscar Health Inc (NYSE:OSCR)’s Major holders

Oscar Health Inc insiders hold 2.82% of total outstanding shares, with institutional holders owning 86.79% of the shares at 89.30% float percentage. In total, 86.79% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 17.38 million shares (or 7.5114% of shares), all amounting to roughly $275.03 million.

The next major institution holding the largest number of shares is BLACKROCK INC. with 14.18 million shares, or about 6.1246% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $224.25 million.